Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + Lenvima
pembrolizumab with lenvatinib · Merck / Eisai
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with advanced endometrial cancer that is neither MSI-high nor dMMR, with progression after systemic therapy and no option for curative surgery or radiation.
LAMPGEN ANALYSIS
Why it matters
This converts the earlier accelerated approval of the combination for biomarker-defined advanced endometrial cancer.
What research teams should watch
Verify MSI/MMR classification, systemic treatment history and why curative local treatment is unavailable.
PRIMARY RECORDS